Paclitor 30 Mg (Paclitaxel) Injection

Introduction

Paclitor 30 mg (Paclitaxel) Injection is a sophisticated oncology medication that represents a significant advancement in cancer treatment. Manufactured with precision by Eskayef Pharmaceuticals Ltd. and distributed globally by Orio Pharma, this injectable formulation delivers the powerful antimicrotubule agent paclitaxel to effectively combat various cancer types. With its unique mechanism of action targeting cellular division processes, Paclitor has become an essential component in modern oncology treatment protocols. Supported by Orio Pharma’s commitment to worldwide delivery within 3-7 working days, healthcare providers can ensure timely access to this critical treatment, enhancing patient care and outcomes in the fight against cancer.

Mechanism of Action

Paclitor works through a precisely targeted mechanism that disrupts cancer cell division:

Microtubule Stabilization: Paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes these structures by preventing depolymerization
Cellular Division Inhibition: This stabilization interferes with the normal dynamic reorganization of the microtubule network essential for vital interphase and mitotic cellular functions
Structural Disruption: Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle
Mitotic Interference: Creates multiple asters of microtubules during mitosis, preventing proper cell division
Cell Death Induction: The cumulative effect of these disruptions leads to cell cycle arrest and ultimately apoptosis (programmed cell death)

This multi-faceted action makes Paclitor particularly effective against rapidly dividing cancer cells while working synergistically with other chemotherapeutic agents in combination regimens.

Pharmacokinetic Profile

Understanding Paclitor’s pharmacokinetics helps optimize treatment protocols:

Biphasic Decline: Following intravenous administration, plasma concentrations decline in a characteristic biphasic manner
Initial Distribution Phase: The rapid initial decline represents distribution to peripheral compartments and initial elimination
Extended Action Phase: The later phase reflects relatively slow efflux of paclitaxel from peripheral compartments
Tissue Distribution: Paclitaxel demonstrates high protein binding and extensive tissue distribution
Metabolism: Primarily metabolized by hepatic CYP450 enzymes
Elimination: Predominantly through biliary excretion and fecal elimination

This pharmacokinetic profile supports the dosing schedules established for various cancer types and treatment protocols.

Therapeutic Applications

Paclitor 30 mg is indicated for multiple cancer types, including:

Ovarian Cancer

First-line therapy in combination with platinum compounds
Second-line treatment for metastatic disease after failure of standard therapy
Demonstrates significant response rates in platinum-resistant disease

Breast Cancer

Treatment of node-positive breast cancer as adjuvant therapy
Management of metastatic breast cancer after failure of combination chemotherapy
Can be used in both HER2-positive and HER2-negative disease states

Non-Small Cell Lung Cancer

First-line treatment in combination with platinum compounds
Effective option for advanced or metastatic disease
Demonstrates improved survival metrics compared to conventional therapies

Other Malignancies

Effective in AIDS-related Kaposi’s sarcoma
Demonstrates activity in head and neck cancers
Utilized in certain gastric and esophageal cancers
Emerging applications in additional tumor types

Dosage and Administration

Proper dosing and administration are critical for maximizing therapeutic benefits while minimizing adverse effects:

Standard Dosing Regimens

Ovarian Cancer: 135-175 mg/m² intravenously over 3 hours every 3 weeks
Breast Cancer: 175 mg/m² intravenously over 3 hours every 3 weeks
Non-Small Cell Lung Cancer: 135 mg/m² intravenously over 24 hours, followed by cisplatin, every 3 weeks
AIDS-related Kaposi’s Sarcoma: 135 mg/m² intravenously over 3 hours every 3 weeks, or 100 mg/m² intravenously over 3 hours every 2 weeks

Administration Guidelines

Premedication with corticosteroids, antihistamines, and H2 antagonists is recommended to prevent hypersensitivity reactions
Must be administered through in-line filtration with microporous membrane not exceeding 0.22 microns
Non-PVC containing administration sets and devices should be used
Close monitoring for hypersensitivity reactions during the first 30 minutes of infusion is essential

The 30 mg vial size provides flexibility in dose preparation for various body surface areas and treatment protocols.

Clinical Considerations

Contraindications

Patients with baseline neutrophil counts <1,500 cells/mm³
History of severe hypersensitivity reactions to paclitaxel or other drugs formulated in polyoxyethylated castor oil
Pregnancy and lactation

Adverse Effects

Common side effects include:

Hematological: Neutropenia, leukopenia, thrombocytopenia, anemia
Neurological: Peripheral neuropathy, paresthesia, dysesthesia
Cardiovascular: Abnormal ECG, hypotension, bradycardia
Gastrointestinal: Nausea, vomiting, diarrhea, mucositis
Musculoskeletal: Myalgia, arthralgia, weakness
Dermatological: Alopecia, skin reactions, nail changes
Hypersensitivity: Flushing, dyspnea, hypotension, chest pain
Other: Fatigue, asthenia, injection site reactions

Special Populations

Hepatic Impairment: Dose reduction recommended based on severity
Elderly: May require close monitoring for enhanced toxicity
Pregnancy: Category D – can cause fetal harm
Pediatric: Safety and efficacy not established in children

Preparation and Storage

Proper handling ensures medication stability and safety:

Preparation Guidelines

Should be prepared and administered only by personnel trained in handling cytotoxic agents
Use appropriate aseptic technique
Dilute in 0.9% Sodium Chloride Injection, 5% Dextrose Injection, or 5% Dextrose and 0.9% Sodium Chloride Injection to a final concentration of 0.3-1.2 mg/mL
Prepared solutions may be stored at room temperature for up to 27 hours

Storage Requirements

Store unopened vials between 20-25°C (68-77°F)
Protect from light
Diluted solutions should not be refrigerated as precipitation may occur

Manufacturing Excellence

Paclitor 30 mg is manufactured by Eskayef Pharmaceuticals Ltd., a premier pharmaceutical company with a heritage of excellence since 1990. When Eskayef acquired the Bangladesh operation of SK&F, USA, they continued a tradition of world-class manufacturing and unwavering quality standards. With over three decades of pharmaceutical expertise, Eskayef ensures that each vial of Paclitor meets the highest standards for efficacy, safety, and quality. Their state-of-the-art facilities and stringent quality control processes guarantee consistency and reliability in every batch.

Supply and Distribution

Orio Pharma serves as the dedicated supplier for Paclitor, specializing exclusively in high-quality oncology medications. Founded in 2019, Orio Pharma is committed to making a difference in cancer care through reliable access to essential treatments. Their core values of compassion, integrity, innovation, and collaboration inform every aspect of their service. With a promise of worldwide delivery within 3-7 working days, Orio Pharma ensures that urgent cancer treatments reach healthcare providers promptly, supporting continuity of care and optimal treatment scheduling.

Conclusion

Paclitor 30 mg (Paclitaxel) Injection represents a cornerstone in modern cancer therapy. Its unique mechanism of action targeting microtubule dynamics makes it an essential treatment option across multiple cancer types. The precision manufacturing by Eskayef Pharmaceuticals and dedicated distribution by Orio Pharma ensure that healthcare providers worldwide have access to this high-quality oncology medication. With comprehensive dosing guidelines, detailed safety information, and rapid global delivery, Paclitor continues to play a vital role in improving outcomes for cancer patients. As oncology treatment continues to evolve, Paclitor remains a trusted and effective option in the therapeutic arsenal against cancer.

For complete prescribing information, clinical support, or to place an order, healthcare professionals are encouraged to contact Orio Pharma’s specialized oncology team today.